A factor IX-deficient mouse model for hemophilia B gene therapy

AUTOR(ES)

Wang, Lili

FONTE

The National Academy of Sciences of the USA

RESUMO

We have generated a mouse where the clotting factor IX (FIX) gene has been disrupted by homologous recombination. The FIX nullizygous (−/−) mouse was devoid of factor IX antigen in plasma. Consistent with the bleeding disorder, the factor IX coagulant activities for wild-type (+/+), heterozygous (+/−), and homozygous (−/−) mice were 92%, 53%, and <5%, respectively, in activated partial thromboplastin time assays. Plasma factor IX activity in the deficient mice (−/−) was restored by introducing wild-type murine FIX gene via adenoviral vectors. Thus, these factor IX-deficient mice provide a useful animal model for gene therapy studies of hemophilia B.

Documentos Relacionados

• Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B.
• Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of hemophilia B.
• Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.
• In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
• Hemophilia B (factor IXSeattle 2) due to a single nucleotide deletion in the gene for factor IX.